Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
NASDAQ:ASND
Price:
221.73
USD
2%
Market Closed
Market Cap:
$13.4B
Balance Sheet
Balance Sheet Decomposition
Ascendis Pharma A/S
Ascendis Pharma A/S
Balance Sheet Decomposition is not available for
Ascendis Pharma A/S
Ascendis Pharma A/S
Balance Sheet
Ascendis Pharma A/S
Ascendis Pharma A/S
Currency: EUR
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
15
|
19
|
50
|
120
|
180
|
195
|
278
|
592
|
585
|
446
|
445
|
392
|
560
|
|
| Cash Equivalents |
15
|
19
|
50
|
120
|
180
|
195
|
278
|
592
|
585
|
446
|
445
|
392
|
560
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
134
|
236
|
291
|
7
|
0
|
|
| Total Receivables |
6
|
2
|
2
|
2
|
2
|
2
|
3
|
5
|
7
|
23
|
26
|
56
|
177
|
|
| Accounts Receivables |
6
|
2
|
1
|
1
|
0
|
0
|
0
|
1
|
0
|
2
|
12
|
36
|
166
|
|
| Other Receivables |
0
|
0
|
1
|
1
|
1
|
2
|
3
|
5
|
7
|
21
|
14
|
20
|
11
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
75
|
131
|
209
|
296
|
|
| Other Current Assets |
0
|
0
|
1
|
4
|
2
|
7
|
12
|
13
|
14
|
25
|
32
|
39
|
28
|
|
| Total Current Assets |
21
|
21
|
53
|
126
|
184
|
205
|
293
|
611
|
740
|
806
|
924
|
703
|
1 061
|
|
| PP&E Net |
1
|
2
|
2
|
2
|
2
|
3
|
4
|
45
|
108
|
126
|
129
|
111
|
99
|
|
| PP&E Gross |
1
|
2
|
2
|
2
|
2
|
3
|
4
|
45
|
108
|
126
|
129
|
111
|
99
|
|
| Accumulated Depreciation |
2
|
2
|
3
|
3
|
4
|
4
|
5
|
11
|
20
|
34
|
47
|
72
|
85
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
1
|
1
|
|
| Goodwill |
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
3
|
3
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
2
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
17
|
16
|
125
|
146
|
30
|
6
|
14
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
3
|
3
|
|
| Total Assets |
25
N/A
|
27
+5%
|
59
+120%
|
132
+125%
|
190
+44%
|
211
+11%
|
319
+51%
|
677
+112%
|
980
+45%
|
1 085
+11%
|
1 090
+0%
|
826
-24%
|
1 179
+43%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
3
|
3
|
5
|
8
|
13
|
24
|
20
|
28
|
22
|
59
|
101
|
95
|
96
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
14
|
33
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
7
|
7
|
25
|
407
|
458
|
|
| Other Current Liabilities |
21
|
18
|
8
|
3
|
0
|
0
|
19
|
14
|
24
|
34
|
45
|
221
|
320
|
|
| Total Current Liabilities |
24
|
20
|
13
|
11
|
14
|
24
|
39
|
48
|
53
|
100
|
171
|
737
|
908
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
31
|
85
|
98
|
483
|
223
|
365
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
7
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
3
|
172
|
6
|
5
|
|
| Total Liabilities |
24
N/A
|
20
-14%
|
13
-37%
|
11
-12%
|
14
+18%
|
24
+76%
|
39
+63%
|
80
+105%
|
141
+77%
|
201
+43%
|
826
+311%
|
971
+18%
|
1 285
+32%
|
|
| Equity | ||||||||||||||
| Common Stock |
0
|
1
|
2
|
3
|
4
|
5
|
6
|
1 129
|
1 736
|
2 115
|
2 121
|
2 131
|
2 452
|
|
| Retained Earnings |
1
|
5
|
44
|
117
|
172
|
0
|
0
|
531
|
897
|
1 214
|
1 861
|
2 277
|
2 560
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
22
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
182
|
274
|
0
|
0
|
4
|
4
|
1
|
2
|
|
| Total Equity |
2
N/A
|
6
+294%
|
46
+627%
|
120
+163%
|
177
+47%
|
187
+6%
|
280
+50%
|
597
+113%
|
839
+40%
|
884
+5%
|
263
-70%
|
146
N/A
|
106
+27%
|
|
| Total Liabilities & Equity |
25
N/A
|
27
+5%
|
59
+120%
|
132
+125%
|
190
+44%
|
211
+11%
|
319
+51%
|
677
+112%
|
980
+45%
|
1 085
+11%
|
1 090
+0%
|
826
-24%
|
1 179
+43%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
23
|
23
|
23
|
25
|
32
|
37
|
42
|
48
|
54
|
57
|
57
|
58
|
61
|
|
Switch to:
Switch to:
See Also
Discover More
